Amgen Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Amgen Inc in the second quarter 2026?
Amgen Inc achieved a return on average equity (ROE) of 89.32 % in its second quarter 2026, this is above AMGN's average return on equity of 46.4%.
Amgen Inc s equity during the 12 months ending in the second quarter 2026 are valued at $9 billion

ROE fell compared to the first quarter 2026, despite the net income growth of 30.57% from the first quarter 2026.

Within the Biotechnology & Pharmaceuticals industry 3 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 113, from total ROE ranking in the first quarter 2026 at 119.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	57.35 %	48.06 %	47.32 %	27.79 %	-
Y / Y Net Income Change	65.85 %	5.14 %	112.6 %	13.64 %	91.96 %
Net Income (TTM) in Millions	8,743	7,800	7,711	7,005	6,619
Return On Equity (TTM)	89.32 %	89.41 %	96.65 %	96.19 %	97.92 %
AMGN's Total Ranking	# 113	# 119	# 61	# 65	# 59
Equity (TTM) in Millions	11,688	9,190	8,658	9,619	7,428
Seq. Equity Change	27.18 %	6.14 %	-9.99 %	29.5 %	19.67 %
Seq. Net Income Change	30.57 %	36.46 %	-58.55 %	124.58 %	-17.23 %

Back to AMGN Management Effectiveness >> AMGN's 5 Years Annual ROE >> Compare AMGN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 4
Sector	# 20
Overall	# 113

Return On Equity Statistics
High	Average	Low
246.11 %	46.4 %	6.61 %
(Dec 31 2022)		(Dec 31 2017)

News about Amgen Inc Return on Equity ROE

Amgen and Kyowa Kirins Rocatinlimab Shows Promise in Phase 3 Study Amid Growth in Supplier Performance

In a remarkable development within the biopharmaceutical sector, Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) have disclosed preliminary top-line results from the ASCEND Phase 3 long-term extension study. This study investigates the efficacy of rocatinlimab, an innovative investigational therapy that rebalances T-cells by targeting the OX40 receptor, specifically in adults and adolescents afflicted with moderate to severe atopic dermatitis (AD). Announced on September 9, 2025, the results from this pivotal trial could herald a transformative advancement in the management of AD, a chronic skin condition characterized by inflammation and persistent itch, which affects millions globally.The ASCEND study s findings are especially significant as they come amid a landscape of increasing demand for effective treatments for atopic dermatitis, which has been showing a rising prevalence. As healthcare providers and patients alike seek novel therapeutic options, rocatinlimab demonstrates a potential breakthrough not only due to its unique mechanism of action but also because of the urgent need for solutions that enhance the quality of life for those afflicted.

AMGN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	8,658	5,877	6,232	3,661	6,700
Y / Y Equity Change	47.32 %	-5.7 %	70.23 %	-45.36 %	-28.79 %
Net Income in Millions	7,711	4,090	6,717	6,552	5,893
Y / Y Net Income Change	88.53 %	-39.11 %	2.52 %	11.18 %	-18.87 %
Return On Equity	89.06 %	69.59 %	107.78 %	178.97 %	87.96 %

Back to AMGN Management Effectiveness >> AMGN's 5 Years Annual ROE >> Compare AMGN ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 89.06 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
AMGN's' Return on Equity at Yahoo Finance
AMGN's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for AMGN's Competitors
Subscribers only: Roe for Amgen Inc 's Suppliers
Subscribers only: Return On Equity for AMGN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Actinium Pharmaceuticals Inc	213.46 %
Halozyme Therapeutics Inc	180.63 %
Capforce Inc	168.50 %
Aveanna Healthcare Holdings Inc	150.35 %
Liquidia Corporation	149.64 %
Interpace Biosciences Inc	142.98 %
Oncotelic Therapeutics Inc	124.17 %
Fortress Biotech Inc	118.22 %
Medpace Holdings Inc	110.15 %
Pulmatrix Inc	108.83 %
Arbutus Biopharma Corp	106.04 %
Rigel Pharmaceuticals Inc	96.49 %
Exelixis Inc	93.62 %
Alnylam Pharmaceuticals Inc	93.61 %
Eli Lilly And Company	92.54 %
Amgen Inc	89.32 %
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %

Date modified: 2026-09-13T23:23:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.